isovitexin has been researched along with Cirrhosis, Liver in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Huang, Y; Long, Y; Luo, W; Qiu, Y; Shi, Y; Su, H; Wei, J; Wei, Y; Zhu, W | 1 |
1 other study(ies) available for isovitexin and Cirrhosis, Liver
| Article | Year |
|---|---|
Isovitexin alleviates hepatic fibrosis by regulating miR-21-mediated PI3K/Akt signaling and glutathione metabolic pathway: based on transcriptomics and metabolomics.
Topics: Animals; Glutathione; Hepatic Stellate Cells; Liver Cirrhosis; Metabolic Networks and Pathways; Mice; MicroRNAs; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Transcriptome | 2023 |